DISPOSITION IN NORMAL VOLUNTEERS OF SODIUM AZODISALICYLATE, A POTENTIAL THERAPEUTIC AGENT IN INFLAMMATORY BOWEL-DISEASE

DISPOSITION IN NORMAL VOLUNTEERS OF SODIUM AZODISALICYLATE, A POTENTIAL THERAPEUTIC AGENT IN INFLAMMATORY BOWEL-DISEASE

Dettagli Bibliografici
Autori principali:	Willoughby, C, Aronson, J, Agback, H, Bodin, N, Andersson, E, Truelove, S
Natura:	Journal article
Lingua:	English
Pubblicazione:	1981

Documenti analoghi

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.
di: Willoughby, C, et al.
Pubblicazione: (1982)

Disodium azodisalicylate in ulcerative colitis.
di: Jewell, D, et al.
Pubblicazione: (1981)

THE DISPOSITION AND METABOLISM OF SULPHASALAZINE (SALICYLAZOSULFAPYRIDINE) IN MAN
di: Khan, A, et al.
Pubblicazione: (1982)

Drugs as causative agents and therapeutic agents in inflammatory bowel disease
di: Phani Krishna Kondamudi, et al.
Pubblicazione: (2013-09-01)

The effect of nifedipine on the disposition of strontium gluconate used as a kinetic marker for calcium in healthy volunteers.
di: Moraes, M, et al.
Pubblicazione: (1991)

Extracellular Vesicles: Novel Potential Therapeutic Agents in Inflammatory Bowel Diseases
di: Irene Mignini, et al.
Pubblicazione: (2023-12-01)

Therapeutic efficacy of jeoryeong-tang in dextran sulfate sodium-induced mouse model of inflammatory bowel disease
di: Il-Woong Jang, et al.
Pubblicazione: (2025-01-01)

Therapeutic targets in inflammatory bowel disease
di: Daniela Fluxa, et al.
Pubblicazione: (2019-07-01)

Deciphering Microbial Composition in Patients with Inflammatory Bowel Disease: Implications for Therapeutic Response to Biologic Agents
di: Orazio Palmieri, et al.
Pubblicazione: (2024-06-01)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
di: Chang Soo Eun
Pubblicazione: (2017-01-01)

Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease
di: Katie Lloyd, et al.
Pubblicazione: (2020-11-01)

Bicervical Normal Uterus with Normal Vagina and Anteroposterior Disposition of the Double Cervix
di: José Morales-Roselló, et al.
Pubblicazione: (2011-01-01)

The discovery of the foxglove as a therapeutic agent
di: Aronson, J
Pubblicazione: (1987)

Therapeutic Drug Monitoring in Inflammatory Bowel Disease
di: Manoel Alvaro de Freitas Lins Neto, et al.
Pubblicazione: (2023-12-01)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
di: Marafini I, et al.
Pubblicazione: (2020-06-01)

Evolving Therapeutic Strategies in the Inflammatory Bowel Disease
di: Soo-Young Na, et al.
Pubblicazione: (2018-02-01)

Catechins and Their Therapeutic Benefits to Inflammatory Bowel Disease
di: Fei-Yan Fan, et al.
Pubblicazione: (2017-03-01)

Sodium phosphate solution as bowel preparation for outpatient diagnostic and therapeutic manipulations
di: N. V. Topchy, et al.
Pubblicazione: (2017-12-01)

Advances in biological agents in the treatment of inflammatory bowel disease
di: Na LI, et al.
Pubblicazione: (2022-08-01)

The Role of Biologics Agent in the Treatment of Inflammatory Bowel Disease
di: Tri Hapsoro Guno, et al.
Pubblicazione: (2017-12-01)

Therapeutic Potential of Triptolide as an Anti-Inflammatory Agent in Dextran Sulfate Sodium-Induced Murine Experimental Colitis
di: Bufu Tang, et al.
Pubblicazione: (2020-11-01)

Neurochemical studies in normal volunteers
di: Nutt, D, et al.
Pubblicazione: (1988)

Development of Ac2-26 Mesoporous Microparticle System as a Potential Therapeutic Agent for Inflammatory Bowel Diseases
di: Broering MF, et al.
Pubblicazione: (2024-04-01)

Translating immunology into therapeutic concepts for inflammatory bowel disease
di: Uhlig, HH, et al.
Pubblicazione: (2018)

Genetically engineered bacteria as inflammatory bowel disease therapeutics
di: Zhen-Ping Zou, et al.
Pubblicazione: (2024-12-01)

Ferroptosis: A therapeutic opportunity of inflammatory bowel disease
di: Yulin Ye, et al.
Pubblicazione: (2024-04-01)

Endoscopic Therapeutic Approach for Dysplasia in Inflammatory Bowel Disease
di: Sung Noh Hong
Pubblicazione: (2017-09-01)

Inflammasome Regulation: Therapeutic Potential for Inflammatory Bowel Disease
di: Qiuyun Xu, et al.
Pubblicazione: (2021-03-01)

Editorial: Novel Therapeutic Approaches in Inflammatory Bowel Diseases
di: Giovanni Pallio
Pubblicazione: (2023-09-01)

Gut microbiome–based therapeutics in inflammatory bowel disease
di: Kelly A. Hu, et al.
Pubblicazione: (2023-04-01)

Nutritional approach as therapeutic manipulation in inflammatory bowel disease
di: Jin Young Yoon
Pubblicazione: (2019-10-01)

The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease
di: Tao Zuo, et al.
Pubblicazione: (2018-09-01)

The microbiota in inflammatory bowel disease: current and therapeutic insights
di: Lane ER, et al.
Pubblicazione: (2017-06-01)

THE DISPOSITION OF ORAL RUBIDIUM CHLORIDE IN ESSENTIAL-HYPERTENSION
di: Boon, N, et al.
Pubblicazione: (1982)

The dispositional effects of holidays on investor sentiment: Therapeutic and hygienic
di: Qing Liu, et al.
Pubblicazione: (2023-04-01)

CYP2B6*6 genotype specific differences in artemether‐lumefantrine disposition in healthy volunteers
di: Abdullahi, ST, et al.
Pubblicazione: (2019)

Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics
di: Jürgen B. Bulitta, et al.
Pubblicazione: (2019-07-01)

THE EFFECT OF DIGOXIN ON THE INVIVO DISPOSITION OF AN ORAL LOAD OF RUBIDIUM CHLORIDE
di: Aronson, J, et al.
Pubblicazione: (1982)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
di: Al Sulais E, et al.
Pubblicazione: (2020-01-01)

Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease.
di: Mahida, Y, et al.
Pubblicazione: (1989)